Loading patent…
AssigneeYeda Research and Development Co. Ltd.
InventorsMichael Sela, Yosef Yarden, Bilha Schechter, Ruth Maron
Estimating the term…
An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.
An article-of-manufacture comprising a packaging material identified for treating cancer expressing EGFR and ErbB-2, packaging:
A pharmaceutical composition comprising as active ingredients:
A method of treating cancer expressing EGFR and ErbB-2 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of:
A method of treating pancreatic cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of:
A method of treating pancreatic cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a single anti ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 N12 (CNCM Deposit Number I-4112), thereby treating cancer in the subject.
Dependencies are inferred from the claim text.